Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?

INTRODUCTION: In metastatic renal cell carcinoma (mRCC), the bone is the second most common site of metastasis and is associated with increased morbidity and poorer quality of life. Bone-targeted therapies (BTTs) such as denosumab and zoledronic acid may prevent skeletal-related events (SREs). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Emily C.L., Kapoor, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931200/
https://www.ncbi.nlm.nih.gov/pubmed/31869748
http://dx.doi.org/10.1016/j.tranon.2019.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931200/
https://www.ncbi.nlm.nih.gov/pubmed/31869748
http://dx.doi.org/10.1016/j.tranon.2019.10.009

Ejemplares similares